A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
Public ClinicalTrials.gov record NCT05718570. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-national, Multi-centre, Prospective, Single-arm, Observational, Non-interventional Post-authorisation Safety Study to Investigate Long-term Safety of Sogroya® (Somapacitan) in Adults With Growth Hormone Deficiency (AGHD) Under Routine Clinical Practice
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
In this study, the general long-term safety and effectiveness of Sogroya (somapacitan) in adults with growth hormone deficiency (AGHD) being treated per normal clinical practice is looked into. In the study, information on side effects and how well Sogroya (somapacitan) works during long term treatment in people with Adult Growth Hormone Deficiency (AGHD) will be collected and analysed. Participants will be treated with Sogroya (somapacitan) as prescribed by the study doctor, in accordance with normal clinical practice. The study will last for 5-10 years, depending on when the participant join the study. The participant will be asked to complete two short questionnaires during every visit to the clinic. The questionnaires will collect information on the participant's well-being, work ability and ability to perform daily activities.
Study identification
- NCT ID
- NCT05718570
- Recruitment status
- Enrolling by invitation
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2, 2023
- Primary completion
- Dec 14, 2032
- Completion
- Dec 14, 2032
- Last update posted
- Jun 11, 2026
2023 – 2032
United States locations
- U.S. sites
- 29
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Barrow Neurological Institute | Phoenix | Arizona | 85013 | — |
| Keck Medical Center of USC - Outpatient Clinic | Los Angeles | California | 90033 | — |
| UCLA Health | Los Angeles | California | 90095 | — |
| Stanford Univ School of Med | Palo Alto | California | 94304 | — |
| Advanced Rx Clinical Research | Westminster | California | 92683 | — |
| Anschutz Outpatient Pavilion | Aurora | Colorado | 80045 | — |
| Metabolic Research Institute Inc | West Palm Beach | Florida | 33401 | — |
| Atlanta Diabetes Associates | Atlanta | Georgia | 30318 | — |
| Northwestern Medical Group | Chicago | Illinois | 60642 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Brigham & Women's Hospital | Boston | Massachusetts | 02115 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| UNMC | Omaha | Nebraska | 68198 | — |
| Palm Research Center Inc-Vegas | Las Vegas | Nevada | 89148 | — |
| Northern Nevada Endocrinology | Reno | Nevada | 89511 | — |
| NYU Langone Orthopedic Center | New York | New York | 10017 | — |
| Cornell University | New York | New York | 10021 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27514 | — |
| Physicians East Endocrinology | Greenville | North Carolina | 27834 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| St Lukes Physician Group | Center Valley | Pennsylvania | 18034 | — |
| Revival Research Institute, LLC | Dallas | Texas | 75231 | — |
| UT Southwestern Medical Center-CRU | Dallas | Texas | 75390 | — |
| EP Premier Medical Group PA | El Paso | Texas | 79935 | — |
| Consano Clinical Research, LLC | Shavano Park | Texas | 78231 | — |
| Puget Sound VA, University of Washington | Seattle | Washington | 98108-1597 | — |
| University Of Washington_Seattle | Seattle | Washington | 98195-6165 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05718570, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05718570 live on ClinicalTrials.gov.